natgillin/translations-raw huggingface dataset:
An antisense oligonucleotide for reducing expression of abnormally spliced LMNA mRNA, the oligonucleotide having a substantially uncharged backbone and being composed of morpholino subunits and phosphorus-containing intersubunit linkages joining a morpholino nitrogen of one subunit to a 5'-exocyclic carbon of an adjacent subunit, containing 25-40 bases, and comprising a targeting sequence comprising any one of SEQ ID NOs: 4, 5, 10, 11, 13, 14, and 16, wherein the antisense oligonucleotide is covalently attached to a cell-penetrating peptide and linker moiety, wherein the linker moiety is selected from glycine, cysteine, proline, 6-aminohexanoic acid (Ahx), B-alanine (B), and Ahx-B, and the cell-penetrating peptide is selected from SEQ ID NOs: 39-54. 
Protusmjerni oligonukleotid za smanjenje ekspresije abnormalno upletene LMNA mRNA, te oligonukleotid ima uglavnom nanabijenu okosnicu i sastavljen je od morfolino podjedinica i veza između podjedinica koje sadrže fosfor koje spajaju morfolino dušik jedne podjedinice na 5'-egzociklički ugljik susjedne podjedinice, koji sadržava 25-40 baza, te koji sadrži ciljajuću sekvencu koja sadrži bilo koju od SEQ ID NOs: 4, 5, 10, 11, 13, 14, i 16, pri čemu je protusmjerni oligonukleotid kovalentno vezan na peptid koji prodire u stanicu i skupine poveznice, pri čemu je skupina poveznice odabrana iz niza koji čine glicin, cistein, prolin, 6-aminoheksanoična kiselina (Ahx), B-alanin (B), i Ahx-B, te peptid koji prodire u stanicu je odabran od SEQ ID NOs: 39-54.
The long term storage stable non-aqueous liquid bendamustine-containing composition of claim 7, wherein the stabilizing amount of the antioxidant is from 5 mg/mL to 20 mg/mL. 
Stabilan pri dugotrajnom skladištenju, nevodeni tekući pripravak s bendamustinom prema zahtjevu 7, naznačen time, da je stabilizirajuća količina antioksidansa od 5 mg/mL do 20 mg/mL.
In certain embodiments, the carbohydrate (and optionally, an antioxidant) is present in an amount sufficient to have stability comparable to that of a lyophilized composition comprising about 0.01 % polysorbate-20, pH 6.0, 50 mM Citrate. 
Farmaceutska kompozicija prema zahtjevu 1, pri čemu je ugljikohidrat prisutan u količini koja je dovoljna da ona ima stabilnost koja odgovara onoj za liofiliziranu kompoziciju koja sadrži saharozu, 0,01 % polisorbata-20, pH 6,0, 50 mM citrata.
This provides easy access for the operator to connect or remove either bottle 20 A or B to device 10 . As indicated at FIG. 
To osigurava lagani pristup operateru da priključi ili da ukloni jednu od boca 20A ili 20B u, ili iz uređaja 10.
The immunogenic composition of claims 1-4 wherein the carrier protein is selected from the group consisting of: TT, DT, CRM197, fragment C of TT and protein D. The immunogenic composition of claims 1-5 wherein the carrier protein is TT. 
Imunogeni pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što saharid Hib je konjugiran s proteinskim nosačem kojeg se bira iz skupine koju čine TT, DT, CRM197, C fragment proteina TT, protein D, OMPC i pneumolizin.
monitoring the catalyst temperature using a temperature sensor in or near the catalyst so that an increase in temperature triggers an increase in air input to the catalyst to reduce the temperature. 
- < praćenje temperature katalizatora korištenjem osjetnika temperature u katalizatoru ili blizu katalizatora tako da povećanje temperature izaziva povećanje dovoda zraka u katalizator da bi se ta temperatura smanjila.
The compound of claim 1, wherein Rx is: 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je spoj formule:
The receiving method according to one of claims 9-13, wherein when one cluster is allocated to the terminal, the resource allocation information is signaled using the available bits only; and the determining includes determining the resource allocation information based on the available bits. 
Postupak prijenosa prema jednom od zahtjeva 9 do 13, naznačen time da kad se dodjeljuje jedan klaster, podatak o dodjeli resursa signalizira se korištenjem dostupnih bitova u polju dodjele resursa isključivo.
A method for producing 1-(2-deoxy-2-halogeno-4-thio-B-D-arabinofuranosyl) cytosine represented by the following formula [14]: wherein R3 has the same meanings as those described below which comprises allowing a compound represented by the following formula [4]: wherein R1a represents a hydroxyl-protecting group; R2a represents a hydroxyl-protecting group; or R1a and R2a may together form an optionally substituted C1-3 alkylene group; and R3 represents a halogen atom, to react with a compound represented by the following formula [5]: 
Metoda za proizvodnju 1-(2-deoksi-2-halogeno-4-tio-B-D-arabinofuranozil) citozina koji je predstavljen sljedećom formulom [14]: gdje R3 ima ista značenja kao ona opisana ispod koja obuhvaća omogućavanje spoju koji je predstavljen sljedećom formulom [4]: gdje R1a predstavlja hidroksil-zaštitnu grupu; R2a predstavlja hidroksil-zaštitnu grupu; ili R1a i R2a mogu zajedno formirati po izboru supstituiranu C1-3 alkilensku grupu; i R3 predstavlja atom halogena, da reagira sa spojem koji je predstavljen sljedećom formulom [5]:
PCT/ GB2005/000464 has the ability to arrest or slow down the development of at least some of the symptoms of Huntington's disease. 
PCT/GB2005/000464 ima sposobnost zaustaviti ili usporiti razvoj barem nekih od simptoma Huntington-ove bolesti.
A self-propelled working machine according to claim 1, wherein said step board (11) exhibits a planar structure, which defines, in the extracted position, a supporting surface walkable by the operator and wherein said axis of rotation (12) is substantially parallel to said step board (11). 
Radni stroj na vlastiti pogon u skladu sa patentnim zahtjevom 1, pri čemu navedeno gazište (11) stepenice pokazuje planarnu strukturu, koja definira, u izvučenom položaju, potpornu površinu po kojoj operater može hodati i pri čemu je navedena os (12) rotacije u suštini paralelna sa navedenim gazištem (11) stepenice.
In this position as shown in Fig. 7 water under pressure can enter the capsule 24 and the interaction with the beverage ingredients contained in the capsule 24 can commence. 
U tom položaju, kao što je to prikazano na slici 7, voda pod pritiskom može ući u čahuru 24 1 može početi interakcija sa sastojkom napitka koji je sadržan u čahuri
A pharmaceutical composition comprising a compound of any one of claims 1 to 12 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. 
[image] Farmaceutski sastav sadrži tvar iz bilo kojeg od patentnih zahtjeva 1 do 37, ili njenu farmaceutski prihvatljivu sol.
Use of E 87, wherein the therapeutic agent is capable of alleviating at least one symptom of the AOID and is a steroid, a non-steroidal anti-inflammatory or a TNF inhibitor. 
Uporaba u skladu sa zahtjevom 87, naznačena time, da je terapeutsko sredstvo sposobno ublažiti barem jedan simptom AOID te je steroid, ne-steroidno protu-upalno sredstvo ili TNF inhibitor.
The method of claim 16, wherein the at least one delivery-enhancement agent comprises hyaluronidase. The method of claim 17, wherein the at least one delivery-enhancement agent further comprises one of the group consisting of hyaluronidase, migration-inducing activity and neuregulin. 
Farmaceutski pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 13, naznačen time što je sredstvo za poboljšavanje unosa najmanje jedno iz skupine koju čine hijaluronidaza, lipofilna sredstva, čimbenik inhibicije leukemije, aktivator migracije i neuregulin.
A composition comprising at least one compound according to any one of claims 1 to 6, optionally further comprising at least one pharmaceutically acceptable carrier. 
Sastav sadrži barem jednu tvar u skladu s bilo kojim od patentnih zahtjeva 1 do 6, opcionalno nadalje sadrži barem jedan farmaceutski prihvatljivi nosač.
Even more preferably, the sealing of an open end, is done by inserting a pre-fabricated end plug at the open end of the hollow tube and by applying an appropriate light-initiated and/or heat-initiated thermoset polyurethane formulation on interface between the pre-fabricated end plug and the open end and initiating and curing with light and/or heat or any other means to seal the ends, preferably permanently. 
€) podešavanje i početno nalijevanje dobijenog uređaja za oslobađanje lijeka da se postignu željene stope oslobađanja jednog ili više aktivnih sastojaka; pri čemu je zaptivanje otvorenog kraja, izvedeno umetanjem unaprijed pripremljenog krajnjeg čepa na otvorenom kraju šuplje cijevi ili primjenom svijetlosti ili topline.
Lock (1) according to Claim 3 or 4, wherein the distance between the pivot pins of the flaps (9-12) of different closing elements (7, 8) is at least equal to the dimensions of a flap (9-12) transversely to the pivot pin. 
Zatvarač (1) u skladu s patentnim zahtjevom 3 ili 4, kod kojeg je udaljenost između hvatišta osovine preklopnika (9-12) različitih elemenata zatvaranja najmanje jednaka dimenzijama preklopnika (9-12) poprečno na hvatište osovine.
Vesicles comprising epidermal growth factor (EGF), a cationic surfactant and cholesterol or derivatives thereof. 
Čestice koje sadrže epidermalni faktor rasta (EGF), kationski surfaktant i kolesterol ili njihove derivate.
Use according to claim 1 wherein the animal to be protected is livestock. 
Uporaba prema zahtjevu 1, naznačena time, da se kod životinje koja se treba zaštititi, radi o stočnim domaćim životinjama.
IL-18BP is constitutively expressed in the spleen, and belongs to the immunoglobulin superfamily. 
Gen za IL-18BP se eksprimira konstitutivno u slezeni, a spada u imunoglobulinsku super obitelj.
Carpet (1) as claimed in claim 8, wherein the high (2) and low (3) piles are arranged optionally in pairwise manner in a chessboard pattern or random structure. 
Tepih (1) prema zahtjevu 8, naznačen time, da su visoki (2) 1 niski (3) flor raspoređeni po izboru, u paru poput šahovske ploče ili u nasumice odabranom rasporedu.
Thus, in addition to known mineral or organomineral fertilizers, there should also be separately incorporated into the soil biostimulants comprising e.g. 
Stoga je, pored poznatih mineralnih, odnosno organsko-mineralnih gnojiva, u tlo potrebno unašati biostimulatore, medu koje spadaju npr.
• cytological examination of the cervix 
* - citološko ispitivanje grlića maternice,
capturing the received input video bit stream prior to decoding and supplying it to a video bit stream analyzer; 
(a) hvatanje primljenog ulaznog bita videosignala prije dekodiranja i njegovo prenošenje u analizator bita videosignala;
The compound or pharmaceutically acceptable salt thereof according to any one of (I) to (IV), wherein R2 is a phenyl group, a pyridyl group, a pyridazinyl group or a pyrimidyl group (said phenyl group, pyridyl group or pyrimidyl group may be substituted by 1-3 halogen atoms or methoxy groups), a pyridonyl group, or a pyrimidinonyl group; 
Spoj ili njegova farmaceutski prihvatljiva sol prema bilo kojem od zahtjeva 1 do 4, naznačen time da R, je fenil skupina, piridil skupina, piridazinil skupina ili pirimidil skupina (navedena fenil skupina, piridil skupina ili pirimidil skupina mogu biti supstituirane s 1-3 atoma halogena ili metoksi skupinama), piridonil skupina, ili pirimidinonil skupina.
A process utilizing at least five moles of at least one starting material for preparing an aminoboronic ester compound of formula (VIIa) or (VIIb): or an acid addition salt thereof, wherein: 
PZ-N H 48. Postupak koji koristi najmanje pet mola najmanje jednog početnog materijala za pripremu spoja ostera aminoorganoborne kiseline formule (VIIa) ili (VIIb):
A method of preparing a pharmaceutical composition, said method comprising admixing a GPR119 agonist, a DPP-IV inhibitor and one or more other pharmaceutically or physiologically acceptable compound selected from the group consisting of: biguanide, sulfonylurea, meglitinide, alpha-glucosidase inhibitor, thizaolidinedione, insulin analog and chromium picolinate/biotin, together with at least one pharmaceutically acceptable carrier, wherein said DPP-IV inhibitor is not identical to 1-[2-[5-cyanopyridin-2-yl)amino]ethylamino]acetyl-2-cyano-(S)-pyrrolidine (NVP-DPP728). 
Postupak priprave farmaceutskog pripravka, naznačen time, da navedeni postupak obuhvaća miješanje GPRI19 agonista i DPP-IV inhibitora skupa s barem jednom farmaceutski prihvatljivom podlogom, pri čemu navedeni DPP- IV inhibitor nije identičan s 1-[2-[(5-cijanopiridin-2-iljamino jetilamino |acetil-2-cijano-(S)-pirolidinom (NVP- DPP728).
This means that even small cracks in the cavity, will be filled with filler particles (and monomer resin). 
To znači da će čak i mala napuknuta u šupljini biti napunjena česticama za punjenje (i monomerna smola).
A sealed container according to embodiment 13, wherein the thickness of the seal layer is from 15 µm to 50 µm, preferably 20 µm. 
Posuda prema bilo kojem od prethodnih Zahtjeva, gdje je debljina sloja za spajanje fitma poklopca od 15 um do 50 um, a poželjno 20 um.
Serine (S) or Threonine (T) at heavy chain amino acid position 144. 
(c) -serin (S) ili treonin (T) na aminokiselinskoj poziciji 144 jakog lanca.
Compound according to claim 1 having one of the following formula's selected from the group of: 
Spoj prema zahtjevu 1 naznačen time da ima jednu od slijedećih formula koje su odabrane iz skupine koju čine:
The process of either one of claim 2 or 28, the process further comprising operating the cooler to cool the warm pyrolyzed solids with steam, thereby generating the cool pyrolyzed solids and superheated steam; wherein the drying is carried out, at least in part, with the superheated steam derived from the cooler. The process of claim 50, wherein the cooler is operated to first cool the warm pyrolyzed solids with steam to reach a first cooler temperature, and then with air to reach a second cooler temperature, wherein the second cooler temperature is lower than the first cooler temperature and is associated with a reduced combustion risk for the warm pyrolyzed solids in the presence of the air. 
hladi navedene tople pirolizirane krute tvari s parom kako bi se stvorile hladne pirolizirane krute tvari i pregrijana para i pri čemu se korak sušenja provodi, barem dijelom, s navedenom pregrijanom parom; i/ili prvo hladi navedene tople pirolizirane krute tvari s parom do postizanja prve temperature hladnjaka, i zatim sa zrakom do postizanja druge temperature hladnjaka, pri čemu je navedena druga temperatura hladnjaka niža od navedene prve temperature hladnjaka i povezana je sa smanjenim rizikom izgaranja za navedene tople pirolizirane krute tvari u prisutnosti navedenog zraka.
θ range for data collection 
Veličina kristala 0 raspon za bazu podataka
With respect to the previous apparatus, there are no cables which could be accidentally detached and therefore compromise its operation; therefore it is more reliable. 
U odnosu na prijašnji uređaj, ovdje nema kabela koji se mogu slučajno odvojiti i na taj način ugroziti rad uređaja; stoga je ovaj uređaj pouzdaniji.
The method of claim 9 directed to the treatment of Alzheimer's disease. 
Spoj za primjenu iz patentnog zahtjeva 9 usmjeren na liječenje Alzheimerove bolesti.
Adhesive composition in form of a gel according to one or more of the previous claims 1-5, 7-9, 11-12, wherein the adhesion promoter/water weight ratio ranges from 25:75 to 60:40, preferably equal to 50.56: 49.44. Adhesive composition in form of a paste according to one or more of the previous claims 1-4, 6-8, 10-11, wherein water is present in amount ranging from 10 to 30% by weight, preferably from 15 to 25% by weight, still more preferably equal to 23% by weight, with respect to the total weight of the adhesive composition. 
Adhezivna kompozicija u obliku gela u skladu sa jednim ili više prethodnih patentnih zahtjeva 1-5, 7-9, 11-12, pri čemu je maseni odnos adhezivni promoter/voda u rasponu od 25:75 do 60:40, poželjno jednako 50.56: 49.44, Adhezivna kompozicija u obliku paste u skladu sa jednim ili više prethodnih patentnih zahtjeva 1-4, 6-8, 10-I1, pri čemu je voda prisutna u količini u rasponu od 10 do 30% po masi, poželjno od 15 do 25% po masi, još poželjnije jednako 23% po masi, u odnosu na ukupnu masu adhezivne kompozicije.
Pimobendan for use in a method according to claim 5, wherein the furosemide is administered in a dosage between 0.5 to 5 mg/kg bodyweight once or twice daily. 
Pimobendan za uporabu u postupku prema zahtjevu 5, naznačen time, da se furosemid primjenjuje u dozi od 0,5 do 5 ug/kg tjelesne mase jednom dnevno ili dva puta dnevno.
The use of an extract of the microalga Aphanizomenon Flos Aquae Aquae Ralfs ex Born. 
Upotreba ekstrakta mikroalge Aprazomenon Flos Aquae Aquae alfs ex Born.
An apparatus for mixing a material, wherein the apparatus comprises a mixing portion comprising a second container and the device as in claim 1; wherein the second container has a downstream outlet defining an opening and is sealably connected to the device around and proximal to the upstream apertures of the device in such a way that the device restricts the opening of the downstream outlet of the second container to the openings of the upstream apertures of the device; and the apparatus functions in such a way that when the mixing portion of the apparatus contains a material, the material can be discharged from the apparatus via the device without clogging the device. 
Postupak kao u zahtjevu 11, naznačen time, da koristi aparat za pre-disperziju i punjenje pre-disperzije u prvi spremnik, pri čemu je aparat učinkovit za miješanje materijala i pri čemu aparat podrazumijeva uređaj i dio za miješanje koji sadrži drugi spremnik; pri čemu drugi spremnik ima ispust nizvodno koji definira otvor i nepropusno je spojen oko i u blizini otvora uzvodno na uređaju na način da uređaj ograničava otvaranje ispusta nizvodno drugog spremnika prema otvorima uzvodno na uređaju; i aparat djeluje na takav način da se, kada drugi spremnik aparata sadrži materijal, materijal može biti ispušten iz aparata putem uređaja bez začepljenja uređaja.
The pharmaceutically acceptable transdermal composition of claim 8, wherein the active agent is carbidopa, levodopa, or a pharmaceutically acceptable salt thereof. 
Farmaceutski prihvatljiv transdermalni sastav iz zahtjeva 8, naznačeno time da je aktivni sastojak karbidop, levodop ili jedna od njihovih farmaceutski prihvatljivih soli.
The method of claim 2, further comprising freezing and thawing the eluate from the HIC column comprising the AvPAL variant obtained in step (e), wherein one or more polyols or sugars selected from the group consisting of glycerol, sucrose, glucose, trehalose, mannitol and sorbitol are added to the HIC column eluate prior to freezing. 
Postupak u skladu s patentnim zahtjevom 2 ili 3, naznačen time što se dodatno sastoji u smrzavanju i odmrzavanju eluata iz HIC stupca koji sadrži varijantu AvPAL dobivenu u koraku (e), gdje se jedan ili više poliola ili šećera koje se bira iz skupine koju čine glicerol, saharoza, glukoza, trehaloza, manitol i sorbitol dodaje eluatu iz HIC stupca prije smrzavanja.
A pharmaceutical composition according to claim 7 comprising an amount of the compound of formula I, or pharmaceutically acceptable solvates, salts, N-oxides or steoreoisomers thereof, or combinations thereof, sufficient to provide a dose of 100 ng/kg to 50 mg/kg, preferably 10 µg/kg to 5 mg/kg of the compound to the subject. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 9, naznačen time što sadrži količinu spoja formule I, ili njegovih farmaceutski prihvatljivih solvata, soli, N-oksida ili stereoizomera, ili njihovih kombinacija, dovoljnu da osigura dozu od otprilike 100 ng/kg do otprilike 50 mg/kg, po mogućnosti otprilike 10 µg/kg do otprilike 5 mg/kg spoja za subjekta.
The resultant accumulation of calcium and other ions in the cell can result in cell swelling and the inappropriate activation of cellular enzymes. 
Resultat akumulacije kalcija i drugih iona u stanici može imati za posljedicu bubrenje stanice i nepravilnu aktivaciju staničnih enzima.
A delayed release drug formulation as claimed in Claim 5, wherein the buffer is potassium dihydrogen phosphate. 
Formulacija lijeka s odloženim otpuštanjem sukladno u jednom od prethodnih patentnih zahtjeva, naznačeno time, da je pufer kalij dihidrogen fosfat.
Compound for use according to Claim 1, characterized in that X1 is an alkyl group having from 1 to 3 carbon atoms, optionally substituted with one or more alkyl groups having from 1 to 3 carbon atoms or one or more alkoxy groups having 1 or 2 carbon atoms. 
Spoj prema zahtjevu 1, naznačen time, da X1 je alkil-skupina koja ima od jednoga do tri atoma ugljika, opcijski supstituirana s jednom ili više alkil-skupina koje imaju od jednoga do tri atoma ugljika ili s jednom ili više alkoksi-skupina koje imaju od jednoga do dva atoma ugljika.
Preparation of the Mesylate salt of Isomer B 
Priprema mesilat soli Izomera B
A compound according to claim 2 having the structure or a pharmaceutically acceptable salt or solvate thereof. 
Spoj u skladu s patentnim zahtjevom 2, sa strukturom ili njegova farmaceutski prihvatljiva sol ili solvat.
the reaction of a compound of the formula (X) with a compound of the formula (XI) or an N-protected derivative thereof: wherein A, E, and R1 to R5 are as defined in any one of claims 1 to 48, one of the groups X and Y is selected from chlorine, bromine, iodine and trifluoromethanesulphonate, and the other one of the groups X and Y is a boronate ester or boronic acid residue, in the presence of a palladium catalyst and a base; 
H (xD (X) u prisutnosti paladijevog katalizatora i baze, gdje su A, E, i R! do R? kako su definirani u bilo kojem od zahtjeva L do 48, jedna od skupina X i Y je izabrana između klora, broma, joda i trifluorometansulfonata, a druga od skupina X i Y je boronat ester ili ostatak boronske kiseline;
In some embodiments, 1 equivalent of the compound of formula 3 is combined with a 1.1 equivalents of NH2OH.HCl in a 10:1 v/v mixture of THF/water. Step 4 
Postupak u skladu s patentnim zahtjevom 11, naznačen time, da se 1 ekvivalent spoja formule 3b kombinira sa 1,1 ekvivalenta NH2OH-HCI u 10: 1 v/v mješavini THF / voda.
While candidiasis usually remains confined to the mouth, it can spread to the esophagus and other parts of the gastrointestinal tract and to the respiratory system, posing more serious problems. 
Dok kandidijaza najčešće ostaje ograničena na usta, može se proširiti na jednjak 1 ostale dijelove gastrointestinlnog trakta te u dišni sustav, stvarajući ozbiljnije probleme.
The process of any one of claims 1-8 containing a further step of mixing the conjugate with further antigens optionally wherein the further antigens comprises at least 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 S.pneumoniae saccharides selected from the group consisting of 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F and 33F. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1-7, naznačen time što uključuje dodatni korak miješanja konjugata s dodatnim antigenima, gdje dodatni antigeni mogu sadržavati najmanje 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 ili 20 saharida iz bakterije S. pneumoniae, koje se bira iz skupine koju čine 1, 2, 3, 4, 5, GA, 6B, TF, 8, JN, JV, 10A, ITA, 12F, 14, 15B, 1I7F, 18C, 19A, 19F, 20, 22F, 23F 1 33F.
Because the inventive fuel element is relatively short, the hot, burning fire cone is always close to the aerosol generating means, which maximizes heat transfer thereto and maximises the resultant production of aerosol, especially in embodiments which are provided with a member conducting heat from the fuel element to the aerosol generating means. 
Zato što je poželjan gorivi element relativno kratak, vruć konus koji gori je uvijek blizak sredstvu za generiranje aerosola, što maksimira prijenos topline na njega i maksimira posljedičnu proizvodnju aerosola, naročito u realizacijama koje su osigurane sa članom za provođenje topline.
The compound according to claim 4 or a pharmacologically acceptable salt thereof, wherein R8a represents an ethyl group, and k represents 0. 
Spoj prema zahtjevu 3 ili njegova farmakološki prikladna sol, gdje R* predstavlja etilnu skupinu, i k predstavlja 0.